CRISPR Therapeutics (CRSP) Receives New Coverage from Analysts at Goldman Sachs

Goldman Sachs started coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report issued on Friday morning. The firm issued a buy rating and a $86.00 price objective on the stock.

Several other equities analysts have also commented on the stock. ValuEngine raised shares of CRISPR Therapeutics from a sell rating to a hold rating in a research report on Monday, April 2nd. TheStreet raised shares of CRISPR Therapeutics from a d+ rating to a c rating in a research report on Friday, March 16th. Zacks Investment Research raised shares of CRISPR Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th. SunTrust Banks reaffirmed a buy rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Finally, Piper Jaffray reaffirmed an overweight rating and issued a $53.70 price objective (down from $67.00) on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $63.95.

How to Become a New Pot Stock Millionaire

Shares of CRISPR Therapeutics stock traded up $0.60 during midday trading on Friday, hitting $43.27. The company had a trading volume of 2,771,686 shares, compared to its average volume of 1,142,825. The firm has a market capitalization of $2,012.61, a P/E ratio of -25.30 and a beta of 3.56. CRISPR Therapeutics has a 12-month low of $13.50 and a 12-month high of $61.24.

In other CRISPR Therapeutics news, insider Tyler Dylan-Hyde sold 66,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the completion of the transaction, the insider now directly owns 25,204 shares of the company’s stock, valued at approximately $706,468.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 39.98% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC raised its position in CRISPR Therapeutics by 26.4% during the 4th quarter. Millennium Management LLC now owns 95,130 shares of the company’s stock worth $2,234,000 after buying an additional 19,858 shares during the last quarter. Paloma Partners Management Co purchased a new position in CRISPR Therapeutics during the 4th quarter worth approximately $290,000. Raymond James & Associates raised its position in CRISPR Therapeutics by 70.2% during the 4th quarter. Raymond James & Associates now owns 82,838 shares of the company’s stock worth $1,945,000 after buying an additional 34,178 shares during the last quarter. Two Sigma Investments LP purchased a new position in CRISPR Therapeutics during the 4th quarter worth approximately $1,079,000. Finally, Morgens Waterfall Vintiadis & Co. Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter worth approximately $704,000. 26.61% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “CRISPR Therapeutics (CRSP) Receives New Coverage from Analysts at Goldman Sachs” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3338715/crispr-therapeutics-crsp-receives-new-coverage-from-analysts-at-goldman-sachs.html.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Chubb  Posts Quarterly  Earnings Results, Beats Expectations By $0.08 EPS
Chubb Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
Six Flags  Issues Quarterly  Earnings Results
Six Flags Issues Quarterly Earnings Results
Comparing ConvergeOne  & AgroFresh Solutions
Comparing ConvergeOne & AgroFresh Solutions
Analysts Set $59.00 Target Price for pdvWireless
Analysts Set $59.00 Target Price for pdvWireless
$559.12 Million in Sales Expected for Ferroglobe  This Quarter
$559.12 Million in Sales Expected for Ferroglobe This Quarter
Financial Contrast: NXT-ID  versus Allegion
Financial Contrast: NXT-ID versus Allegion


© 2006-2018 Ticker Report. Google+.